Century Therapeutics Inc. (IPSC) carries a Roarable Rating of E (Strong Sell) with 18/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Century Therapeutics Inc. (NASDAQ: IPSC) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 18/100 at a spot price of $1.47 (+0.69% 1D, market cap $266.2M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 4/20, SEC Balance-Sheet Forensics 5/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, IPSC ranks #999 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), IPSC carries a Roarable E (18/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -14.1%. By comparison, LXEO (Lexeo Therapeutics Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $257.6M) and CABA (Cabaletta Bio Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $256.0M). Among the 5-stock peer group, IPSC leads on earnings multiple (N/A) while IPSC leads on capital efficiency (-14.1% ROIC).
Per IPSC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001850119), Century Therapeutics Inc. generated $109.2M in revenue (+1556.8% YoY), -$9.6M in net income, and -$104.7M in free cash flow against $223.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
FRED Regime × Technicals: 40% of 52W Range • RSI-14 at 44.9 (NEUTRAL RANGE)
Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 3/9
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While IPSC currently carries a cautious 18/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.71) and Max Pain ($1.54) forces dealer call-delta covering toward $3.19.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Century Therapeutics Inc. (IPSC) advanced +0.69% to $1.47, trading at 40% of its 52-week range ($0.44 – $3.04). Stretched risk/reward at current multiples (-14% return on capital) under elevated 10-year interest-rate pressure.
Yahoo! Finance Canada report covering Century Therapeutics Inc. (IPSC) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering Century Therapeutics Inc. (IPSC) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Century Therapeutics Inc. (IPSC) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance Australia report covering Century Therapeutics Inc. (IPSC) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Century Therapeutics Inc. (IPSC) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering Century Therapeutics Inc. (IPSC) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering Century Therapeutics Inc. (IPSC) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering Century Therapeutics Inc. (IPSC) market action, institutional positioning, and fundamental catalysts.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +1556.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on IPSC today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for IPSC. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, Century Therapeutics Inc. (IPSC) ranks #999 by composite RQD confidence (18/100, grade E) and #530 by equity capitalization ($266.2M). Within this direct 5-issuer industry benchmark cohort, IPSC leads on earnings valuation at N/A trailing P/E, while IPSC leads on capital efficiency and profitability with -14.1% ROIC and — gross margin. FATE currently holds the highest overall quantitative score in the immediate peer group at 35/100 (D-) compared with IPSC at 18/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| IPSC
ACTIVE
Century Therapeutics Inc. | E | 18/100 | — | — | -14.1% | +0.69% | $266.2M | Benchmark Subject |
| LXEO Lexeo Therapeutics Inc. | E | 33/100 | — | — | -35.0% | +2.61% | $257.6M | /lxeo-vs-ipsc → |
| CABA Cabaletta Bio Inc. | E | 33/100 | — | — | -35.0% | -4.73% | $256.0M | /caba-vs-ipsc → |
| LCTX Lineage Cell Therapeutics Inc. | E | 20/100 | — | — | -35.0% | -2.91% | $252.9M | /lctx-vs-ipsc → |
| FATE Fate Therapeutics Inc. | D- | 35/100 | — | — | -35.0% | -4.15% | $249.2M | /fate-vs-ipsc → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Century Therapeutics Inc. (IPSC) reported GAAP revenue of $109.2M (+1556.8% vs. FY2024 revenue of $6.6M , and +4784.3% cumulative change since FY2023) , GAAP net income of -$9.6M, operating cash flow of -$103.9M, and free cash flow of -$104.7M (+5.0% YoY). On the balance sheet, IPSC closed FY2025 with $223.7M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $109.2M | -$9.6M | -$103.9M | -$104.7M | $223.7M | — |
| FY2024 (FY) | 2024-12-31 | $6.6M | -$126.6M | -$110.1M | -$110.3M | $353.2M | — |
| FY2023 (FY) | 2023-12-31 | $2.2M | -$136.7M | -$88.3M | -$88.3M | — | — |
As of 2026-11-03, Century Therapeutics Inc. (NASDAQ: IPSC) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 18/100 at a spot price of $1.47 (+0.69% 1D, market cap $266.2M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 4/20, SEC Balance-Sheet Forensics 5/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, IPSC ranks #999 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), IPSC carries a Roarable E (18/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -14.1%. By comparison, LXEO (Lexeo Therapeutics Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $257.6M) and CABA (Cabaletta Bio Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $256.0M). Among the 5-stock peer group, IPSC leads on earnings multiple (N/A) while IPSC leads on capital efficiency (-14.1% ROIC).
Per IPSC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001850119), Century Therapeutics Inc. generated $109.2M in revenue (+1556.8% YoY), -$9.6M in net income, and -$104.7M in free cash flow against $223.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
IPSC last traded at $1.47 (+0.69% on volume of 951,161 shares), positioning the stock -14.04% below its 50-day simple moving average ($1.71) and -29.67% below its 200-day simple moving average ($2.09). Across its 52-week range of $0.44 to $3.04, IPSC sits at the 39.6% percentile with a 14-day RSI of 44.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.29 to $1.65).
Century Therapeutics Inc. (IPSC) earns a live Roarable RQD composite score of 18/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $1.47 (+0.69% 1D, market capitalization $266.2M).
Century Therapeutics Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Biological Products (No Diagnostic Substances) industry. It has a market capitalization of $0.3B. —: specific products, customers, and revenue model details are not described in the source data.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Century Therapeutics Inc. (IPSC) reported $109.2M in annual revenue (up from $6.6M in FY2024, +1556.8% YoY) and -$9.6M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($2.2M revenue, -$136.7M net income) through FY2025, IPSC scaled operating cash flow to -$103.9M and free cash flow to -$104.7M, backed by $223.7M in total assets against $0 in total debt.
— The Butterfly Supply-Chain Graph lists no upstream or downstream dependencies, no sector correlations, and no second-order links.
Real-time company headlines, analyst actions, and sector developments for Century Therapeutics Inc. (IPSC) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo! Finance Canada report covering Century Therapeutics Inc. (IPSC) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering Century Therapeutics Inc. (IPSC) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Century Therapeutics Inc. (IPSC) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance Australia report covering Century Therapeutics Inc. (IPSC) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Century Therapeutics Inc. (IPSC) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering Century Therapeutics Inc. (IPSC) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering Century Therapeutics Inc. (IPSC) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering Century Therapeutics Inc. (IPSC) market action, institutional positioning, and fundamental catalysts.
The street is overcomplicating Century Therapeutics Inc. (IPSC). Revenue rose to $109.2M in FY 2025 from $6.6M in FY 2024, and cash of $61.9M is reported for FY 2025.. With an RQD score of 18/100 (E) and Forensic Balance Sheet at 5/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $1.59.
@CreditSpread_Watch Shorting a 4/20 institutional whale-flow stock at $1.47 is dangerous when funds are rotating into Health Care.
I respect the product at Century Therapeutics Inc., but the stock at $1.47 is a different story. Operating losses persisted in every reported period, FCF was -$104.7M in FY 2025, and the Altman Z-Score of 0.2 signals forensic balance sheet risk.. FCF yield is 0.0% and RQD sits at 18/100 (E) — why pay up here when you can wait for next quarter's numbers?
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).